Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2

Is tirzepatide (TZP 5, 10, 15mg) efficacious in reducing HbA1c and body weight (BW) compared to placebo (PBO) and semaglutide 1mg (SEMA) in people with type 2 diabetes (T2D) irrespective of baseline beta-cell function?